The North America Narcolepsy Therapeutics Market would witness market growth of 9.8% CAGR during the forecast period (2022-2028).
There are two different forms of narcolepsy recognized by the International Classification of Sleep Disorders-Third Edition diagnostic criteria: type 1 and type 2. Chronic daily extreme sleepiness lasting less than three months, mean sleep latency of fewer than eight minutes, and two or more sleep-onset rapid eye movements on the Multiple Sleep Latency Test are all criteria that all types share. The cataplexy and/or low levels of hypocretin 1 in the cerebrospinal fluid (CSF) are additional diagnostic criteria for NT1 (orexin A).
The NT2 criteria include the absence of cataplexy, normal or unmeasured levels of hypocretin 1 in the CSF and the absence of any other condition (including medication side effects or discontinuation) that could explain the results of the EDS and/or MSLT. Many people who have narcolepsy also have unsteady, interrupted sleep, which can include frequent nighttime awakenings. The daily activities of narcoleptics can be affected. People who have narcolepsy may unintentionally nod off while engaging in activities like talking, eating, or driving.
The treatment for sleep disorders is in greater demand in both the United States and Canada. The market is expected to be driven by the rising prevalence of narcoleptic disorders, higher awareness, and high healthcare spending. The other elements projected to support revenue growth include favorable reimbursement regulations for treatments, a solid clinical pipeline, and rising stress levels. The high frequency of narcolepsy in industrialized nations like the United States would encourage more people to use narcolepsy treatments, fueling the expansion of this market.
The US market dominated the North America Narcolepsy Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,071.6 million by 2028.The Canada market is poised to grow at a CAGR of 12.3% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 11.3% during (2022 - 2028).
Based on Type, the market is segmented into Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy. Based on Product, the market is segmented into Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Central Nervous System Stimulants, Tricyclic Antidepressants and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Narcolepsy Therapeutics Market is Estimated to reach $5 Billion by 2028, at a CAGR of 10.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Jazz Pharmaceuticals plc, Shionogi & Co., Ltd., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc. (Arena Pharmaceuticals, Inc.), Bioprojet, Takeda Pharmaceutical Company Limited, Ligand Pharmaceuticals, Inc., and Graymark Healthcare, Inc.
By Type
By Product
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 